# Weekly Evidence Report



Health Technology Assessment Philippines

12 to 18 June 2021

#### **Overview**

The following report presents summaries of evidence the Department of Health (DOH) - Health Technology Assessment (HTA) Unit reviewed for the period of 12 to 18 June 2021. The HTA Unit reviewed a total of 9 studies for the said period.

Evidence includes 3 studies on Epidemiology; 0 studies on Transmission; 2 studies on Drugs; 0 studies on Vaccines, 0 studies on Equipment and Devices; 1 study on Medical and Surgical Procedures; 2 studies on Traditional Medicine; and 1 study on Preventive & Promotive Health.

The following report notes that 4 studies have not been peer-reviewed, each highlighted accordingly.



#### **Sections**

**Epidemiology** 

Transmission

Drugs

**Vaccines** 

Equipment & Devices

Medical & Surgical Procedures

**Traditional Medicine** 

Preventive & Promotive Health

## **Evidence on Epidemiology**

Local COVID-19 Tracker: <a href="https://www.doh.gov.ph/covid19tracker">https://www.doh.gov.ph/covid19tracker</a>
Local COVID-19 Case Tracker: <a href="https://www.doh.gov.ph/covid-19/case-tracker">https://www.doh.gov.ph/covid-19/case-tracker</a>

Date	Author/s	Title	Journal/ Article Type	Summary	
X XXX 2021	WHO Global	Coronavirus Disease 2019 (COVID-19) External Situation Report	WHO Global (Situation Report)	•	

16 Jun 2021	ASEAN Biodiaspora Virtual Center	Risk Assessment for International Dissemination of COVID-19 to the ASEAN Region	ASEAN Biodiaspora Virtual Center (Risk Assessment)	•	Malaysia noted that once cases fall below 4,000 per day, the lockdown in the country would be eased Laos initiated that persons in contact with infected persons would be quarantined at either a quarantine center or hotel.  Brunei has extended the suspension of border movement and travels in the country in borders with India, Nepal, Sri Lanka, Pakistan, and Bangladesh
----------------	--	---	--	---	---

## **Evidence on Vulnerable Population Epidemiology**

Date	Author/s	Title	Journal/ Article Type	Summary
16 Jun 2021	Misra, P.	Serological prevalence of SARS-CoV-2 antibody among children and young age (between age 2-17 years) group in India: An interim result from a large multi-centric population-based seroepidemiological study	MedRxiv (Seroepid emiologic al Study)	<ul> <li>The ongoing serosurveillance study has 4,500 of the proposed total population of 10,000.</li> <li>Interim data among aged 2-17 years old showed that seroprevalence of 55.7% in those younger than 18 years of age and 63.5% in those 18 years of age or older were noted.</li> <li>No statistical significant difference was found in prevalence between children and adults</li> </ul>
Note. Studies	that have not been peer-re	viewed are highlighted in red.		Back to Sections page

#### **Evidence on Transmission**

Date	Author/s	Title	Journal/ Article Type	Summary

## **Evidence on Drugs**

Date	Author/s	Title	Journal/ Article Type	Summary
15 Jun 2021	Blumberg, EA, et al	Phase I Trial of Cyclosporine for Hospitalized Patients with COVID-19	MedRxiv (Clinical Trial)	<ul> <li>A single-site, single-arm, open label study was conducted in hospitalized adult patients given a 25mg and 100mg capsules of cyclosporine was conducted</li> <li>Majority of adverse events were minor and did not require the stopping of intake of the drug</li> <li>An advantage for the drug is its cost effectiveness which makes it a potential drug for low to limited resource settings</li> </ul>
17 Jun 2021	Fischer, WA II, et al	Molnupiravir, an Oral Antiviral Treatment for COVID-19	MedRxiv (Clinical Trial)	<ul> <li>202 participants were randomized 1:1 to either 200 mg molnupriavir or placebo or 3:1 molnupiravir (400 or 800 mg)</li> <li>At day 5 of the study, the virus was not isolated from those taking 400 or 800 mg compared to placebo</li> <li>The drug was well tolerated with similar counts in adverse events as the placebo group</li> </ul>

#### **Evidence on Vaccines**

### **NYT Coronavirus Vaccine Tracker:**

https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html

## **Bloomberg Vaccine Tracker:**

https://www.bloomberg.com/graphics/covid-vaccine-tracker-global-distribution/

London School of Hygiene and Tropical Medicine Vaccine Trial Mapper and Tracker: <a href="https://vac-lshtm.shinyapps.io/ncov-vaccine-landscape/">https://vac-lshtm.shinyapps.io/ncov-vaccine-landscape/</a>

#### **ACIP Files:**

https://drive.google.com/drive/u/0/folders/1v-jd66qllxnUkfzXWKqiD0mkVvqy VvJ

Date	Author/s	Title	Journal/ Article Type	Summary	

## **Evidence on Medical and Surgical Procedures**

Date	Author/s	Title	Journal/ Article Type	Summary
14 Jun 2021	Ramanathan, K, et al	Extracorporeal membrane oxygenation for COVID-19: a systematic review and meta-analysis	Critical Care (Systematic Review and Meta-analysis)	<ul> <li>22 observational studies with 1,896 patients were included in the review and meta-analysis</li> <li>The pooled-in hospital mortality among COVID-19 patients on ECMO was noted to be 37.1% (95% CI: 32.3-42.0)</li> </ul>

## **Evidence on Equipment & Devices**

Date	Author/s	Title	Journal/ Article Type	Summary

#### **Evidence on Traditional Medicine**

Date	Author/s	Title	Journal/ Article Type	Summary
16 Jun 2021	Lucas, K, et al	Ceylon cinnamon and its major compound Cinnamaldehyde can limit overshooting inflammatory signaling and angiogenesis in vitro: implications for COVID-19 treatment	MedRxiv (Clinical study)	<ul> <li>A final concentration of 0.2% and 0.3% were incubated with Ceylon cinnamon extracts (CCE)wherein cells were observed in their reaction to the exposure to the cinnamaldehyde</li> <li>It was noted that CCE can dampen the activation of TLR4-dependent pathways during inflammation</li> </ul>
16 Jun 2021	Singh, RS, et al	Promising traditional Indian medicinal plants for the management of novel Coronavirus disease: A systematic review	Phytotherapy Research (Systematic Review)	<ul> <li>22 traditional Indian medicinal plants were included in the review from 35 studies</li> <li>Potential uses for the medicinal herbs like the Ocimum tenuiflorum, Justicia adhatoda, Momordica charantia, and others are suggested as therapies against COVID-19</li> </ul>

#### **Evidence on Preventive & Promotive Health**

## **Evidence on Screening**

Date	Author/s	Title	Journal/ Article Type	Summary
				<del></del>

#### **Evidence on Personal Measures**

Date	Author/s	Title	Journal/ Article Type	Summary
				<del></del>

## **Evidence on Community Measures**

Date	Author/s	Title	Journal/ Article Type	Summary
11 Jun 2021	Stoltenberg, C et al	Scandinavian research about the consequences of COVID-19 on welfare, equality, social conditions, and quality of lifefirst update: systematic literature search with categorization	FHI (Systematic Literature Search)	<ul> <li>26 studies were included coming from Denmark, Norway, and the rest from several countries</li> <li>The review listed the sources found naming 12 cross sectional studies on adults but the search did not push through with full text reviews</li> </ul>